This is echoed in more recent data from prospective LS databases demonstrating a cumulative incidence of bladder cancer (at age 75) of 8.1% among EPCAM/MSH2 carriers compared to 4.1% in MLH1 carriers [24,30]. Here, MSH2 is linked to urinary bladder carcinoma.